Cargando…

The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients

PURPOSE: The objective of this study was to evaluate external beam radiotherapy (EBRT) in lung cancer patients who suffer from airway obstruction. MATERIALS AND METHODS: Medical data of 95 patients with a lung mass that obstructed the airway and received EBRT for it were analyzed. Fifty-nine patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jeong Won, Lee, Jong Hoon, Kim, Hoon-Kyo, Shim, Byoung Yong, An, Ho Jung, Kim, Sung Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398100/
https://www.ncbi.nlm.nih.gov/pubmed/25544583
http://dx.doi.org/10.4143/crt.2013.261
Descripción
Sumario:PURPOSE: The objective of this study was to evaluate external beam radiotherapy (EBRT) in lung cancer patients who suffer from airway obstruction. MATERIALS AND METHODS: Medical data of 95 patients with a lung mass that obstructed the airway and received EBRT for it were analyzed. Fifty-nine patients (62.1%) had non-small cell lung cancer and 36 patients (37.9%) had small cell lung cancer. Radiotherapy was given at 8 to 45 Gy (median, 30 Gy) in 1 to 15 fractions (median, 10 fractions). The response to EBRT was assessed through changes in radiographic findings and/or subjective symptoms between before and after EBRT. The median follow-up duration was 124 days. The primary end point was the airway-obstruction resolving rate after EBRT. The secondary end points were patient survival and toxic effects of EBRT. RESULTS: Improvement of airway obstruction after EBRT on chest X-ray was achieved in 75 of 95 patients (78.9%). The median time for resolving the radiologic findings and/or symptoms of airway obstruction after EBRT was 7 days (range, 1 to 76 days). The 1-year survival rate was significantly higher in responders than non-responders (12.5% vs. 0.0%, p < 0.001). The biologically effective dose of ≥ 39 Gy(α/β=10) (p < 0.01) and the longest obstructive lesion of < 6 cm (p=0.04) were significantly associated with a good response to EBRT in resolving the airway obstruction. No one had grade 3 or higher acute and chronic toxicities. CONCLUSION: EBRT is an effective treatment in relieving airway obstruction without severe toxicities in lung cancer patients.